Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026)

Arcus Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $79.0 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 9.72% year-over-year to $79.0 million in Q1 2026; TTM through Mar 2026 was $79.0 million, a 9.72% increase from a year earlier, with the FY2025 full-year figure at $78.0 million, down 75.55% from the prior year.
• Current Deferred Revenue advanced to $79.0 million in Q1 2026 per RCUS's latest filing, from $78.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $429.0 million in Q3 2023 and bottomed at $35.0 million in Q2 2023.
• The 5-year median for Current Deferred Revenue is $97.0 million (2022), against an average of $168.6 million.
• Across the five-year window, Current Deferred Revenue jumped 834.29% in 2024 and slumped 80.33% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $97.0 million in 2022, then slumped by 63.92% to $35.0 million in 2023, then jumped by 811.43% to $319.0 million in 2024, then tumbled by 75.55% to $78.0 million in 2025, then gained by 1.28% to $79.0 million in 2026.
• Per Business Quant, the three latest RCUS Current Deferred Revenue figures stand at $79.0 million (Q1 2026), $78.0 million (Q4 2025), and $105.0 million (Q3 2025).